BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malik A, Thanekar U, Amarachintha S, Mourya R, Nalluri S, Bondoc A, Shivakumar P. "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Front Oncol 2020;10:627701. [PMID: 33718121 DOI: 10.3389/fonc.2020.627701] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu B, Wang S, Xu M, Ma Y, Sun R, Ding H, Li L. The double-edged role of hydrogen sulfide in the pathomechanism of multiple liver diseases. Front Pharmacol 2022;13:899859. [PMID: 36588686 DOI: 10.3389/fphar.2022.899859] [Reference Citation Analysis]
2 Volponi C, Gazzillo A, Bonavita E. The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network. Cancers (Basel) 2022;14. [PMID: 36551635 DOI: 10.3390/cancers14246151] [Reference Citation Analysis]
3 Shao X, Zhu J, Shi Y, Fang H, Chen J, Zhang Y, Wang J, Jian H, Lan S, Jiang F, Zhong F, Zhang Y, Cao C. Upregulated UBE4B expression correlates with poor prognosis and tumor immune infiltration in hepatocellular carcinoma. Aging (Albany NY) 2022;14:9632-46. [PMID: 36470669 DOI: 10.18632/aging.204414] [Reference Citation Analysis]
4 Zhang X, Wen J, Zhang G, Fan W, Tan J, Liu H, Li J. Identification and Validation of Novel Immunogenic Cell Death- and DNA Damage Response-Related Molecular Patterns Correlated with Immune Status and Prognosis in Hepatocellular Carcinoma. Transl Oncol 2022;27:101600. [PMID: 36481605 DOI: 10.1016/j.tranon.2022.101600] [Reference Citation Analysis]
5 Wang L, Geng G, Zhu T, Chen W, Li X, Gu J, Jiang E. Progress in Research on TLR4-Mediated Inflammatory Response Mechanisms in Brain Injury after Subarachnoid Hemorrhage. Cells 2022;11. [PMID: 36497041 DOI: 10.3390/cells11233781] [Reference Citation Analysis]
6 Xue L, He J, Chen H, Ren C, Fu X. Circ_0003998 upregulates ARK5 expression to elevate 5-Fluorouracil resistance in hepatocellular carcinoma through binding to miR-513a-5p. Anti-Cancer Drugs 2022;33:1103-1113. [DOI: 10.1097/cad.0000000000001359] [Reference Citation Analysis]
7 Xiao Z, Yeung CLS, Yam JWP, Mao X. An update on the role of complement in hepatocellular carcinoma. Front Immunol 2022;13:1007382. [DOI: 10.3389/fimmu.2022.1007382] [Reference Citation Analysis]
8 Sas Z, Cendrowicz E, Weinhäuser I, Rygiel TP. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. Int J Mol Sci 2022;23:3778. [PMID: 35409139 DOI: 10.3390/ijms23073778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Qian X, Yang Z, Gao L, Liu Y, Yan J. The role of complement in the clinical course of hepatocellular carcinoma. Immun Inflamm Dis 2022;10:e569. [PMID: 34813686 DOI: 10.1002/iid3.569] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
10 Bao L, Wang M, Fan Q. Hsa_circ_NOTCH3 regulates ZNF146 through sponge adsorption of miR-875-5p to promote tumorigenesis of hepatocellular carcinoma. J Gastrointest Oncol 2021;12:2388-402. [PMID: 34790400 DOI: 10.21037/jgo-21-567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Gao JY, Chang CS, Lien JC, Chen TW, Hu JL, Weng JR. Synthetic Tryptanthrin Derivatives Induce Cell Cycle Arrest and Apoptosis via Akt and MAPKs in Human Hepatocellular Carcinoma Cells. Biomedicines 2021;9:1527. [PMID: 34829756 DOI: 10.3390/biomedicines9111527] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Yu J, Ma S, Tian S, Zhang M, Ding X, Liu Y, Yang F, Hu Y, Xuan G, Zhou X, Wang J, Han Y. Systematic Construction and Validation of a Prognostic Model for Hepatocellular Carcinoma Based on Immune-Related Genes. Front Cell Dev Biol 2021;9:700553. [PMID: 34671598 DOI: 10.3389/fcell.2021.700553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Cui M, Liu D, Xiong W, Wang Y, Mi J. ERRFI1 induces apoptosis of hepatocellular carcinoma cells in response to tryptophan deficiency. Cell Death Discov 2021;7:274. [PMID: 34608122 DOI: 10.1038/s41420-021-00666-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Zhang X, Wang H, Lou L, Li Q, Zhang L, Ge Y. Transcript expression profiling of fibromelanosis-related genes in black-bone chickens. Br Poult Sci 2021;:1-9. [PMID: 34402346 DOI: 10.1080/00071668.2021.1966750] [Reference Citation Analysis]
15 Han J, Zhang X. Complement Component C3: A Novel Biomarker Participating in the Pathogenesis of Non-alcoholic Fatty Liver Disease. Front Med (Lausanne) 2021;8:653293. [PMID: 34395461 DOI: 10.3389/fmed.2021.653293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Blidisel A, Marcovici I, Coricovac D, Hut F, Dehelean CA, Cretu OM. Experimental Models of Hepatocellular Carcinoma-A Preclinical Perspective. Cancers (Basel) 2021;13:3651. [PMID: 34359553 DOI: 10.3390/cancers13153651] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
17 Oura K, Morishita A, Tani J, Masaki T. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci 2021;22:5801. [PMID: 34071550 DOI: 10.3390/ijms22115801] [Cited by in Crossref: 40] [Cited by in F6Publishing: 56] [Article Influence: 20.0] [Reference Citation Analysis]